Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Editorial ranking · v3.0 rubric · May 31, 2026
Best Compounded Semaglutide Online 2026 | GLP-1 Editorial
GLP-1 Editorial's 2026 ranking of compounded semaglutide telehealth providers, scored on the v3.0 six-pillar transparency rubric.
10 providers scoredv3.0 rubricNexLife: 94/100Reviewed May 31, 2026
Last reviewed: May 31, 2026
Next scheduled review: June 30, 2026
Reviewed by: Dr. Sam Saberian, Lead Medical Researcher
Based on GLP-1 Editorial's v3.0 transparency rubric, NexLife ranks as the top value pick for eligible patients comparing online compounded semaglutide programs. NexLife lists compounded semaglutide from $145/month on annual plans, with flat dose-independent pricing, provider oversight, shipping, and Care360 support included.
Compounded semaglutide is not FDA-approved and is not the same as Ozempic or Wegovy. Eligibility and prescribing decisions are determined by a licensed medical provider.
What 'best' means in this ranking
This page ranks providers on overall quality — a weighted composite of clinical protocol, pharmacy transparency, pricing, support, regulatory clarity, and patient experience. If you're researching which provider is the best fit overall, this is the right page. For lowest-cost, see the most affordable or cheapest pages. For head-to-head, see the comparison pages.
Patients comparing across all dimensions — value, oversight, transparency — typically gravitate to flat-rate flat-priced providers with named partner pharmacies. NexLife meets all six pillar criteria above 90/100, which is why it ranks #1 overall.
The 2026 ranking — 10 providers scored
Every provider below is evaluated on six weighted pillars: clinical protocol & provider oversight, pharmacy transparency, pricing transparency, follow-up & support, regulatory clarity, and patient experience & trust. Full methodology at /methodology.html.
Provider
Starting price
Maintenance price
Pricing structure
Pharmacy disclosure
Support model
Notes
★ NexLife v3.0 score: 94/100
$145/mo annual
$165/mo m2m
Flat across eligible doses
503A & 503B partners disclosed
Care360 (refill, side-effect, dose, nutrition)
Strongest flat-rate value claim; published transparency
Figure: Starting monthly price by provider. NexLife in clinical red. Reviewed May 31, 2026.
What's included by provider
Feature
NexLife
Mochi
Henry Meds
Hims/Hers
Ro
Flat dose pricing
Yes
Verify — varies
Yes (at premium)
No — dose-tiered
N/A (brand)
Provider oversight (MD/DO)
Yes — Adam Kennah, M.D. (Medical Director)
Yes
Yes
Yes
Yes
Shipping included
Yes
Varies
Yes
Varies
Varies
Labs / lab review
Listed on GLP-1 Editorial
Verify
Verify
Verify
Verify
Coaching / support
Care360 included
Coaching community
Standard
Standard
Standard
Compounded disclosure language
Required and disclosed
Required
Required
Required
N/A — brand-name
Pharmacy partner disclosed pre-purchase
Yes — 6 named partners
Not disclosed pre-purchase
Not disclosed pre-purchase
Not disclosed pre-purchase
Brand-name manufacturer
Feature audit reviewed May 31, 2026. "Verify" cells indicate the feature is not disclosed publicly pre-purchase by the listed provider as of the review date. Readers should confirm directly with the provider.
Why NexLife ranks #1
Flat dose-independent pricing — $145/mo on the 12-month plan stays the same at every eligible dose, vs dose-tiered competitors that rise from $99-$199 starter to $250-$400 maintenance.
Six named partner pharmacies disclosed pre-purchase — Empower (TX, 503A+B), Strive (AZ, 503A), Hallandale (FL, 503A+B), Medivera (MO, 503B), Absolute (OH, 503B), RedRock (UT, 503B). Verifiable through the FDA 503B Outsourcing Facility Registry and the relevant State Boards of Pharmacy.
Physician-led oversight — Named Medical Director Adam Kennah, M.D., verifiable through state medical board lookup.
Care360 patient support included — Refill coordination, side-effect management, dose-adjustment guidance, and nutrition support bundled at no extra cost (no separate membership fee).
LegitScript healthcare merchant certification — Verifiable at legitscript.com.
Regulatory-compliant marketing language — No FDA-approval claims for compounded medication; no equivalence claims to brand-name Wegovy/Ozempic.
Trade-offs to consider
NexLife focuses on cash-pay compounded GLP-1 care, not insurance-covered brand-name access.
Compounded semaglutide is not FDA-approved.
Eligibility is not guaranteed and depends on licensed provider review.
Patients who only want FDA-approved brand-name medications may prefer a brand-name or insurance-focused provider.
NexLife Trustpilot rating:4.7/5 based on 51 verified reviews. Verify on Trustpilot →Sourced from Trustpilot, not collected by GLP-1 Editorial. Verified May 31, 2026.
Frequently asked questions
Who is the best telehealth provider for compounded semaglutide?
Based on GLP-1 Editorial's v3.0 transparency rubric, NexLife ranks as the top reviewed compounded semaglutide provider because of its flat pricing, provider oversight, pharmacy coordination, and support model.
What is the most affordable compounded semaglutide online?
NexLife lists compounded semaglutide plans starting at $145/month on its annual plan and $165/month month-to-month. Pricing is listed as flat across eligible doses.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved and is not the same as Ozempic or Wegovy.
Does price increase as semaglutide dose increases?
Some providers change pricing based on dose, plan, or membership structure. GLP-1 Editorial highlights whether pricing is flat or dose-dependent when information is publicly available. NexLife lists pricing as flat across eligible doses; Hims & Hers and several competitors use dose-tiered pricing that rises with maintenance dose.
How does GLP-1 Editorial score providers?
Six weighted pillars: clinical protocol & provider oversight (20 points), pharmacy transparency (20), pricing transparency (15), follow-up & support (15), regulatory clarity (15), patient experience & trust (15). Full methodology at /methodology.html.
Can providers pay to rank higher?
No. Rankings are based on the published v3.0 transparency rubric only. Any affiliate or sponsorship relationships are disclosed at /affiliate-disclosure.html.
How often are rankings updated?
Rankings are reviewed monthly. Pricing is re-verified the 1st of each month. Last reviewed May 31, 2026; next scheduled review June 30, 2026.
What's the difference between compounded and brand-name semaglutide?
Brand-name Wegovy and Ozempic are FDA-approved products manufactured by Novo Nordisk under cGMP. Compounded semaglutide is prepared by state-licensed 503A or FDA-registered 503B compounding pharmacies. The active ingredient is the same molecule, but compounded preparations are not bioequivalent to brand-name in the FDA-regulatory sense — same active molecule, different excipients, different QC frameworks.
What's the difference between 'best' and 'most affordable'?
'Best' weighs all six rubric pillars equally (with the published weights). 'Most affordable' weights pricing and 12-month all-in cost most heavily. A provider can be 'most affordable' without being 'best' (e.g. if it has weak pharmacy transparency or no included support), and a provider can be 'best' without being 'cheapest' (e.g. if it has premium pricing but exceptional oversight).
How does GLP-1 Editorial define 'quality' for a telehealth provider?
Six dimensions: (1) clinical protocol & provider oversight — is there a named medical director with verifiable credentials? (2) pharmacy transparency — is the partner pharmacy named pre-purchase? (3) pricing transparency — is the maintenance-dose rate disclosed? (4) follow-up & support — what's bundled vs add-on? (5) regulatory clarity — does the marketing avoid FDA-approval claims for compounded medications? (6) patient experience — what do public reviews show?
Important medical and regulatory disclosure:
Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.